Article
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jul 2022
Mukherjee Semanti, Bandlamudi Chaitanya, Hellmann Matthew D, Kemel Yelena, Drill Esther, Rizvi Hira, Tkachuk Kaitlyn, Khurram Aliya, Walsh Michael F, Zauderer Marjorie G, Mandelker Diana, Topka Sabine, Zehir Ahmet, Srinivasan Preethi, Esai Selvan Myvizhi, Carlo Maria I, Cadoo Karen A, Latham Alicia, Hamilton Jada G, Liu Ying L, Lipkin Steven M, Belhadj Sami, Bond Gareth L, Gümüş Zeynep H, Klein Robert J, Ladanyi Marc, Solit David B, Robson Mark E, Jones David R, Kris Mark G, Vijai Joseph, Stadler Zsofia K, Amos Christopher I, Taylor Barry S, Berger Michael F, Rudin Charles M, Offit Kenneth
Abstract excerpt
BACKGROUND: The genetic factors that modulate risk for developing lung cancer have not been fully defined. Here, we sought to determine the prevalence and clinical significance of germline pathogenic/likely pathogenic variants (PV) in patients with advanced lung cancer. METHODS: We studied clinical and tumor characteristics of germline PV in 5,118 patients who underwent prospective genomic profiling using paired...
Topics
Join the communities discussing this publication.